Russell Investments Group
ABCL icon

Russell Investments Group’s AbCellera Biologics ABCL Stock Holding History

Russell Investments Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9K Buy
+3,431
New +$16.8K ﹤0.01% 3757
2023
Q3 		– Sell
-158
Closed -$1.02K – 3514
2023
Q2 		$1.02K Buy
+158
New +$1.08K ﹤0.01% 3325
2023
Q1 		– Sell
-8,900
Closed -$90.2K – 3283
2022
Q4 		$90.2K Buy
8,900
+3,600
+68% +$41.6K ﹤0.01% 2684
2022
Q3 		$52K Buy
+5,300
New +$58.1K ﹤0.01% 2740

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Russell Investments Group's ABCL Position: Q2 2026 in Review

Russell Investments Group opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 3,431 shares worth $26.9K. The stake represents ﹤0.01% of the portfolio and ranks #3757 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in ABCL as recently as Q2 2023.

Russell Investments Group first reported a position in ABCL in Q3 2022 and has held it in 4 quarters since. The position peaked at $90.2K in Q4 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Russell Investments Group held 3,431 shares of AbCellera Biologics worth $26.9K as of Q2 2026.
  • AbCellera Biologics was a new Russell Investments Group position in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3757 holding.
  • Russell Investments Group first reported a position in AbCellera Biologics in Q3 2022 and has held it in 4 quarters since.
  • Russell Investments Group's AbCellera Biologics position peaked at $90.2K in Q4 2022.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.